Freedman MS - Search Results

1

Can we predict benign multiple sclerosis? Results of a 20-year long-term follow-up study.

Sartori A, Abdoli M, Freedman MS. Sartori A, et al. Among authors: freedman ms. J Neurol. 2017 Jun;264(6):1068-1075. doi: 10.1007/s00415-017-8487-y. Epub 2017 Apr 17. J Neurol. 2017. PMID: 28417192

2

Freedman MS, Thompson EJ, Deisenhammer F, Giovannoni G, Grimsley G, Keir G, Ohman S, Racke MK, Sharief M, Sindic CJ, Sellebjerg F, Tourtellotte WW. Freedman MS, et al. Arch Neurol. 2005 Jun;62(6):865-70. doi: 10.1001/archneur.62.6.865. Arch Neurol. 2005. PMID: 15956157

3

Cerebrospinal fluid analysis in the diagnosis of multiple sclerosis.

Thompson EJ, Freedman MS. Thompson EJ, et al. Among authors: freedman ms. Adv Neurol. 2006;98:147-60. Adv Neurol. 2006. PMID: 16400832 Review. No abstract available.

4

Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparison.

Freedman MS, Hughes B, Mikol DD, Bennett R, Cuffel B, Divan V, LaVallee N, Al-Sabbagh A. Freedman MS, et al. Eur Neurol. 2008;60(1):1-11. doi: 10.1159/000127972. Epub 2008 Apr 25. Eur Neurol. 2008. PMID: 18437041 Review.

5

Multiple sclerosis: following clues from cause to cure.

MacLean HJ, Freedman MS. MacLean HJ, et al. Among authors: freedman ms. Lancet Neurol. 2009 Jan;8(1):6-8. doi: 10.1016/S1474-4422(08)70272-2. Lancet Neurol. 2009. PMID: 19081501 Review. No abstract available.

6

The prognostic significance of cerebrospinal fluid in multiple sclerosis.

Siritho S, Freedman MS. Siritho S, et al. Among authors: freedman ms. J Neurol Sci. 2009 Apr 15;279(1-2):21-5. doi: 10.1016/j.jns.2008.12.029. Epub 2009 Jan 31. J Neurol Sci. 2009. PMID: 19181345

7

MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome.

Nielsen JM, Pohl C, Polman CH, Barkhof F, Freedman MS, Edan G, Miller DH, Bauer L, Sandbrink R, Kappos L, Uitdehaag BM. Nielsen JM, et al. Among authors: freedman ms. BMC Neurol. 2009 May 20;9:19. doi: 10.1186/1471-2377-9-19. BMC Neurol. 2009. PMID: 19457248 Free PMC article. Clinical Trial.

8

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.

Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Radü EW, Metzig C, Bauer L, Lanius V, Sandbrink R, Pohl C; BENEFIT Study Group. Kappos L, et al. Among authors: freedman ms. Lancet Neurol. 2009 Nov;8(11):987-97. doi: 10.1016/S1474-4422(09)70237-6. Epub 2009 Sep 10. Lancet Neurol. 2009. PMID: 19748319 Free article. Clinical Trial.

9

Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.

Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, Hauser S, Waubant E, Vollmer T, Panitch H, Zhang J, Chin P, Smith CH; OLYMPUS trial group. Hawker K, et al. Among authors: freedman ms. Ann Neurol. 2009 Oct;66(4):460-71. doi: 10.1002/ana.21867. Ann Neurol. 2009. PMID: 19847908 Clinical Trial.

10

Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study.

Moraal B, Pohl C, Uitdehaag BM, Polman CH, Edan G, Freedman MS, Hartung HP, Kappos L, Miller DH, Montalban X, Lanius V, Sandbrink R, Barkhof F. Moraal B, et al. Among authors: freedman ms. Arch Neurol. 2009 Nov;66(11):1345-52. doi: 10.1001/archneurol.2009.243. Arch Neurol. 2009. PMID: 19901165

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

337 results

Search Page

Filters